Old Drug Could Be Newest Weapon Against Mesothelioma
A drug that has long been used to address pinworm parasites has shown success in impairing mesothelioma cell growth, report researchers from Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, Philadelphia, who worked with collaborators from the University of Siena, Italy.

“[We] found that the drug affected the expression of downstream genes in the WNT signaling pathway, which are implicated in mesothelioma aggressiveness and its resistance to conventional therapy,” wrote Dr. Antonio Giordano, lead author of the study.
“The results of this study represent a step forward in the development of new treatments for patients with mesothelioma. Pyrvinium pamoate is able to affect important features of mesothelioma aggressiveness, suggesting that the repurposing of this drug for mesothelioma treatment could represent a new promising therapeutic approach,” added Giordano.
“These are encouraging results, especially considering that drug repositioning, using already approved drugs for new indications, is a promising strategy to identify active molecules for a more rapid and less expensive clinical translation compared to de novo drug development,” says study author Marcella Barbarino of the University of Siena.
Indeed, pyrvinium pamoate was developed in the 1960s specifically for the treatment of pinworm infections. However, within the last ten years, scientists have begun to look at it as a potential cancer drug, with several clinical trials conducted about five years ago involving patients with aggressive forms of breast cancer.
The drug has been tested with other types of cancer as well and has been approved as treatment in other countries.
Happily, using a drug that has already been approved for other uses can often eliminate much of the red tape associated with bringing a new drug into the system.
That means the drug can get to patients much more quickly rather than being bogged down for months – or, more likely, years – by the FDA.
Dutch News reports that the Dutch health and safety authorities known as ILT and NVWA have ordered two types of make-up sold by Claire’s to be withdrawn from sale after it found traces of asbestos in the powder.
The authors, a group of doctors and nurses from various Japanese hospitals, sent a questionnaire to hospitals and patient advocacy groups, who distributed them to malignant pleural mesothelioma (MPM) patients considered to be disease-free at this time.
USGS estimates that approximately a million homes in this country contain vermiculite attic insulation. While that number seems small in comparison to the number of homes in the U.S., it’s still an alarming statistic considering the harm it can do when it’s tainted with asbestos.
Dr. Leonard Berry, Distinguished Professor of Marketing at Texas A&M University, called his study “Role of Kindness in Cancer Care”, and in it he emphasizes that high tech treatments must be balanced by high touch care.
A December 22 report on a Rhode Island television news station was sparked by the operations director at a law firm in that state. The person in question, Kristi Warner, told reporters that she sent some of her daughter’s make-up – which she purchased at Claire’s – to a lab for testing after hearing about similar stories concerning low-priced make-up products geared towards young users.
According to an article in the Insurance Journal, the highest court in the State of New York recently ruled that American Home Assurance Company must defend contractors and the Port Authority of New York and New Jersey against asbestos claims that have been brought forward by construction workers who became sick after performing work on the original World Trade Center back some 40-50 years ago.